Thanks to advances in messenger RNA technology, two mRNA vaccines targeting SARS-CoV-2 have played a key role in the response to the COVID-19 pandemic. Rather than using cells to make mRNA, these vaccines use mRNA that is made in cells. in vitro In the laboratory, it is known as in vitro transcribed (IVT) mRNA. A detailed understanding of how IVT mRNA encodes proteins during the translation process (protein production mediated by the ribosomal and transfer RNA machinery) could contribute to future applications of this type of technology. there is.Writing in progress NatureMulroney other.1 We show that ribosomes can stall at “slippery” sequences along modified versions of mRNA (those containing chemically modified nucleoside moieties). This can result in the production of abnormal protein products. For such nucleoside-modified mRNA vaccines and non-vaccine therapeutic RNAs, this may have unintended consequences.
competing interests
DBW is aware of several potentially competing interests, which are managed by the Wistar General Council Secretariat COI Committee. These include consulting, board services, speaking, stock or monetary compensation, and certain of his SRAs. Inovio Pharmaceuticals (Board of Directors, Consultant and SRA); AstraZeneca (Speaker/Consultant); Advaccine (Consultant); Pfizer (Speaker/Advisory Services); Geneos (Consultant and SRA); Flagship (Consultant); Sumitomo Pharmaceuticals (Consultancy); and possibly others managed by the Wistar COI Committee. DBW is a member of scientific societies such as the International Association for Vaccinology, AAI, ASGCT, and AAAS. He is also involved in similar activities at the NIH and his NCI research sections and other institutions.
